NewAmsterdam Pharma N.V., a clinical stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease, listed on NASDAQ, priced and closed its USD 181 million public offering of ordinary shares by certain of the Company’s existing shareholders at a public offering price of $11.50 per common share, which included a partial exercise of the underwriters’ option to purchase additional ordinary shares, granted to the underwriters by certain of the selling shareholders. The Company did not receive any proceeds from the secondary offering. NewAmsterdam Pharma N.V. obtained a listing on NASDAQ in November 2022 through a de-SPAC transaction. With the secondary offering the shareholder base of the company has expanded which will hopefully lead to more liquidity.